Therapeutic use of cannabis: Prevalence and characteristics among adults in ontario, Canada

Canadian Journal of Public Health

Volumn 108, Issue 3, 2017, Pages e282-e287

  Hamilton, Hayley A ^a,b   Brands, Bruna ^a,b,c   Ialomiteanu, Anca R ^a   Mann, Robert E ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HEALTH CANADA   (Canada)

Author keywords

Medical cannabis use; Medical marijuana use; Prescription opioids; Problematic cannabis use

Indexed keywords

MEDICAL CANNABIS; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ADOLESCENT; ADULT; CANNABIS ADDICTION; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; ONTARIO; PREVALENCE; RISK FACTOR; SOCIOECONOMICS; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEDICAL MARIJUANA; MIDDLE AGED; ONTARIO; PRESCRIPTION DRUGS; PREVALENCE; RISK FACTORS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 85029700249     PISSN: 00084263     EISSN: 19207476     Source Type: Journal    
DOI: 10.17269/CJPH.108.6130     Document Type: Article

References (35)

1. United Nations Office on Drugs and Crime. World Drug Report. New York, NY: UNODC, 2014.
2. Center for Behavioral Health Statistics and Quality. Results From the 2015 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUHDetTabs-2015/NSDUH-DetTabs-2015.pdf (Accessed February 2, 2016).
3. Health Canada. Summary of Results for 2013: Canadian Tobacco Alcohol and Drugs Survey (CTADS). Ottawa, ON: Health Canada, 2015. Available at: http://healthycanadians.gc.ca/science-research-sciences-recherches/data-donnees/ctads-ectad/summary-sommaire-2013-eng.php (Accessed July 18, 2016).
4. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA 2015;313(24):2474-83. PMID: 26103031. doi: 10.1001/jama.2015.6199.
5. Health Canada. Understanding the New Access to Cannabis for Medical Purposes Regulations. Ottawa, ON: Health Canada, 2016. Available at: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/understanding-new-access-to-cannabis-for-medical-purposes-regulations.html (Accessed February 2, 2017).
6. Health Canada. Procedures for Accessing Marijuana for Medical Purposes Under the Marihuana for Medical Purposes Regulations. Ottawa, ON: Health Canada, 2016. Available at: http://www.hc-sc.gc.ca/dhp-mps/marihuana/access-acceder-eng.php (Accessed July 18, 2016).
7. Kalant H. Marihuana: Medicine, addictive substance or both? A common-sense approach to the place of cannabis in medicine. Can J Addict 2013;4(3):4-8.
8. Reid A. Medical marihuana: More knowledge and clinical guidance needed. Can J Addict 2013;4(3):21-22.
9. Whiting PF, Wolff RF, Deshpande S, Nisio MD, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015;313(24):2456-73. PMID: 26103030. doi: 10.1001/jama.2015.6358.
10. Health Canada. Information for Health Care Professionals: Cannabis (Marihuana, Marijuana) and the Cannabinoids. Ottawa, ON: Health Canada, 2013. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf (Accessed August 6, 2016).
11. Kalant H, Porath-Waller A. Clearing the Smoke on Cannabis: Medical Use of Cannabis and Cannabinoids. Ottawa, ON: Canadian Centre for Substance Abuse, 2014.
12. Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Deutsch Arzteblatt Int 2012;109(29-30):495-501. PMID: 23008748. doi: 10.3238/arztebl.2012.0495.
13. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010;70(18):2409-38. PMID: 21142261. doi: 10.2165/11585260-000000000-00000.
14. Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag 2009;5(6):341-57. PMID: 20073408.
15. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008;9(3):254-64. PMID: 18088560. doi: 10.1016/j.jpain.2007.10.018.
16. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007;4(1):4-16. PMID: 18292704. doi: 10.1151/ASCP07414.
17. Anthony JC. The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS (Eds.), Cannabis Dependence: Its Nature, Consequences and Treatment. Cambridge, UK: Cambridge University Press, 2006; 58-105.
18. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of Marijuana use disorders in the United States between 20012002 and 2012-2013. JAMA Psychiatry 2015;72(12):1235-42. PMID: 26502112. doi: 10.1001/jamapsychiatry.2015.1858.
19. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study. Drug Alcohol Depend 2013;133(2):352-59. PMID: 23886472. doi: 10.1016/j.drugalcdep.2013.06.009.
20. Ialomiteanu A, Hamilton HA, Adlaf EM, Mann RE. CAMH Monitor eReport: Substance Use, Mental Health and Well-Being Among Ontario Adults, 1977-2013 (CAMH Research Document Series No. 35). Toronto, ON: Centre for Addiction and Mental Health, 2014.
21. Health Canada. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS): Summary of Results for 2012. Ottawa, ON: Health Canada, 2014. Available at: http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2012/summary-sommaire-eng.php (Accessed July 11, 2016).
22. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System: 2013 Summary Data Quality Report. Atlanta, GA: Centers for Disease Control and Prevention, 2014. Available at: https://www.cdc.gov/brfss/annual_data/2013/pdf/2013_dqr.pdf (Accessed July 18, 2016).
23. Ialomiteanu A, Adlaf E. CAMH Monitor 2013 Metadata User’s eGuide. Toronto, ON: Centre for Addiction and Mental Health, 2014.
24. WHO ASSIST Working Group. Alcohol, smoking and substance involvement screening test (ASSIST): Development, reliability and feasibility. Addiction 2002;97:1183-94. PMID: 12199834. doi: 10.1046/j.1360-0443.2002.00185.x.
25. McDowell I. Measuring Health: A Guide to Rating Scales and Questionnaires, 3rd ed. New York, NY: Oxford University Press, 2006.
26. Statacorp. Stata Statistical Software: Release 13.1 [Computer Program]. College Station, TX: StataCorp, 1985-2013.
27. Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): Prevalence of Use and Related Harms: Detailed Report. Ottawa, ON: Canadian Centre on Substance Abuse, 2005.
28. Adlaf E, Begin P, Deguire AE, Garlick R, Racine S, Sawka E, et al. Canadian Addiction Survey: Public Use Microdata File. Ottawa, ON: Canadian Centre for Substance Abuse, 2004.
29. Asbridge M, Duff C, Marsh DC, Erickson PG. Problems with the identification of ‘problematic’ cannabis use: Examining the issues of frequency, quantity, and drug use environment. Eur Addict Res 2014;20(5):254-67. PMID: 25196945. doi: 10.1159/000360697
30. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011;90(6):844-51. PMID: 22048225. doi: 10.1038/clpt.2011.188.
31. Ware MA. Clearing the smoke around medical marijuana. Clin Pharmacol Ther 2011;90(6):769-71. PMID: 22089341. doi: 10.1038/clpt.2011.241.
32. Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in medicare part D. Health Aff 2016;35(7):1230-36. PMID: 27385238. doi: 10.1377/hlthaff.2015.1661.
33. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 2016;17(6):739-44. PMID: 27001005. doi: 10.1016/j.jpain.2016.03.002.
34. Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol 2017;31:569-75. PMID: 28372506. doi: 10.1177/0269881117699616.
35. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy 2017;42:30-35. PMID: 28189912. doi: 10.1016/j.drugpo.2017.01.011.